Company profile
FluoroPharma Medical, Inc.
OTC: FPMI · Healthcare · Biotechnology
PublicHQ Montclair, NJReports USD
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 30
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.0M
Employees
4
as of 2026-08-30
Market cap
$6.9k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02016
Net income-$2.0M-$2.0M2016
Operating income-$2.2M-$2.2M2016
Total assets$334.8k$334.8k2016
Liabilities$10.5M$10.5M2016
Equity-$10.2M-$10.2M2016
Revenue trend
FY2007 – FY2016 · USD
FY07
FY08
FY13
FY14
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is FluoroPharma Medical, Inc.’s revenue?
FluoroPharma Medical, Inc. booked $0 in FY2016 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
HTC Purenergy Inc.——SES Solar Inc.——Nexien BioPharma, Inc.——PAO Group, Inc.——NovAccess Global Inc.——LadRx Corporation——Key facts
CEOEdward L. Lyons Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersMontclair, NJ
ExchangeOTC: FPMI
Employees4
IPO date2011-05-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.